Company: CMND
Filing Date: 2025-11-26
Form Type: 424B5
Source: 0001213900-25-115106
Chunk: 27

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-26
Form: 424B5
Chunk 27
---
 to our most recent Annual Report on Form 20-F incorporated by reference herein for additional information.

Payment of dividends may be subject to Canadian withholding taxes. See “Item 10. – Additional Information – E. “Taxation — Material Canadian Federal Income Tax Considerations” in our most recent Annual Report on Form 20-F incorporated by reference herein for additional information.

<div align='center'>S-15

PLAN OF DISTRIBUTION</div>

We have arranged for the sale of the securities we are offering pursuant to this prospectus supplement to institutional investors through a securities purchase agreement directly between the purchasers and us. All of the shares will be sold at the same price and, we expect, at a single closing. We established the price following negotiations with the prospective investors and with reference to the prevailing market price of our Common Shares, recent trends in such price and other factors. It is possible that not all of the securities we are offering pursuant to this prospectus supplement will be sold at the closing, in which case our net proceeds would be reduced. We expect that the sale of the securities will be completed on or around the date indicated on the cover page of this prospectus supplement.

The Common Shares and/or pre-funded warrants may not be sold in Canada or to or for the benefit of a Canadian resident. By purchasing the securities offered pursuant to this prospectus supplement, the purchaser undertakes not to sell such securities in Canada or to a person resident in Canada prior to the expiry of a period of four months and one day from closing of this offering.

<div align='center'>LEGAL MATTERS</div>

The validity of the issuance of our Common Shares offered hereby and certain other matters of Canadian law will be passed upon for us by Daniel N. Bloch. Certain matters of U.S. federal securities law relating to this offering will be passed upon for us by Greenberg Traurig, P.A., Tel Aviv, Israel.

<div align='center'>EXPERTS</div>

The financial statements of Clearmind Medicine Inc. as of October 31, 2024 and 2023 and for the years then ended, as included in this prospectus supplement, have been audited by Brightman Almagor Zohar & Co., a firm in the Deloitte global network, an independent registered public accounting firm, as stated in their report. Such financial statements are included in reliance upon the report of such firm given the firm’s authority as experts in accounting and auditing.

The audit report covering the October 31, 2024 consolidated